Qiagen N v (QGEN) - News Archive

QIAGEN Celebrates 4,000th QIAcube Connect Placement, Reinforcing Commitment to Automated Sample Processing In a major development within the life sciences and diagnostics sectors, QIAGEN N.V., headquartered in Venlo, Ne...

QIAGEN Achieves CE-IVDR Certification for QIAstat-Dx Portfolio While Expanding Oncology Offerings Through Strategic Partnerships for MRD TestingIn a significant advancement for molecular diagnostics, QIAGEN (NYSE: QGEN;...

A New Chapter for QIAGEN: Stephen Rusckowski Appointed Chairman of Supervisory Board In a significant reshuffle at the helm, QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leader in the life sciences industr...

In a significant stride towards bolstering its oncology diagnostics capabilities, QIAGEN (NYSE: QGEN Frankfurt Prime Standard: QIA) has recently announced the expansion of its portfolio focused on detecting minimal resi...

VENLO, Netherlands QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a front-runner in molecular testing solutions, is making strategic strides to enhance the landscape of oncology research and global health. Thr...

In a remarkable stride towards enhancing quality control in the rapidly evolving fields of cell and gene therapy, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced the expansion of its digital PCR (dPCR)...

In a bold move set to reshape the future of laboratory operations, QIAGEN, a leading global provider of sample and assay technologies, has announced its ambitious plans to launch three new sample preparation instruments...

In a significant advancement for malaria research and public health, QIAGEN N.V. headquartered in Venlo, Netherlands, has announced the launch of its innovative QIAprep Plasmodium Kit. This novel solution, accompanied b...

QIAGEN Expands QIAstat-Dx Operations with New Advanced Facility in Barcelona to Propel Infectious Diseases and Precision Medicine Testing In a bold step to bolster its global presence in the cutting-edge realms of infec...

In a strategic move to bolster its standing in the infectious diseases and precision medicine sectors, QIAGEN N.V. has announced plans to relocate its QIAstat-Dx operations to a newly established facility in Esplugues d...

As the landscape of molecular diagnostics continues to evolve, QIAGEN N.V. is making waves with the introduction of groundbreaking tools tailored for microbial analysis. The company s recent launch of customizable digit...

QIAGEN Advances Microbiome and Diagnostic Research through Strategic Collaborations and Innovations VENLO, Netherlands. QIAGEN, a leader in molecular diagnostics and sample preparation technology, is making significant...

QIAGEN: A Strong Q3 2024 Performance Defies Market Trends In an era characterized by fluctuating market conditions and shifting consumer demands, QIAGEN N.V. has demonstrated remarkable resilience and adaptability. The...

In a pivotal development for emergency diagnostics, QIAGEN has received clearance from the U.S. Food and Drug Administration (FDA) for its QIAstat-Dx Meningitis/Encephalitis Panel. This innovative tool is designed to fa...

As QIAGEN N.V. prepares to release its third-quarter results for 2024, the company is already making waves in the clinical diagnostics industry with groundbreaking technological advancements. Headquartered in Venlo, The...

The year 2024 marks a crucial point in the global fight against tuberculosis (TB), as experts, policymakers, and industry leaders gather for the Global TB Summit. Once considered a disease of the past in many parts of t...

QIAGEN has officially launched its groundbreaking QIAcuityDx digital PCR system, marking a significant advancement in clinical testing for oncology. This innovative platform broadens the range of applications for the hi...

Vilnius, Lithuania, Sept. 26, 2024 Oxylabs, a leading platform in web intelligence collection, has announced the release of a groundbreaking artificial intelligence solution aimed at revolutionizing the way enterprises...

In the illustrious world of modern medicinal technology, an innovation of notable significance has emerged, heralded by PreAnalytiX a revered joint venture by the eminent QIAGEN and BD. The venture has recently unveiled...

In an era where technological advancements are reshaping the landscape of forensic science, the recent partnership between QIAGEN and Bode Technology marks a significant milestone in the realm of forensic genetic geneal...